Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHMP extensions for Roche's Tarceva, Novartis' Afinitor and Wyeth's Enbrel

This article was originally published in Scrip

Executive Summary

Following its meeting on 21st July 2011, the Committee for Medicinal Products for Human Use (CHMP), advisers to the European Commission, gave a positive opinion on the use of Roche's Tarceva (erlotinib) as a first-line treatment in locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. The opinion, which was made public on 22 July, makes it clear that the CHMP believes that the drug has not demonstrated benefit in EGFR-negative tumours.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts